- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03702608
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial
Prospective, Multi-center, Single-arm, Open-label Clinical Trial, to Further Assess the Safety and Efficacy of Long (38 mm) Ridaforolimus Eluting Stent - EluNIR
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel
- Medinol LTD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General Inclusion Criteria:
- Age ≥ 18 years.
- Patient with an indication for PCI including angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, or recent STEMI. For STEMI the time of presentation to the first treating hospital, whether a transfer facility or the study hospital, must be >24 hours prior to enrollment and enzyme levels (CK-MB or Troponin) demonstrating that either or both enzyme levels have peaked.
- An attempt (whether successful or not) was made to implant a 38 mm EluNIR stent (Stent was advanced beyond the guiding catheter).
Non-target vessel PCI are allowed prior to the screening for eligibility depending on the time interval and conditions as follows:
During Baseline Procedure:
PCI of non-target vessels performed during the baseline procedure itself immediately prior to screening for eligibility, if successful and uncomplicated defined as: <50% visually estimated residual diameter stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation, no persistent ST segment changes, no prolonged chest pain, no TIMI major or BARC type 3 bleeding.
- Less than 24 hours prior to Baseline Procedure:
Not allowed (see exclusion criteria #2). c. 24 hours-30 days prior to Baseline Procedure: i. PCI of non-target vessels 24 hours to 30 days prior to the baseline procedure if successful and uncomplicated as defined above.
ii. In addition, in cases where non-target lesion PCI has occurred 24-72 hours prior to the baseline procedure, at least 2 sets of cardiac biomarkers must have been drawn at least 6 and 12 hours after the non-target vessel PCI.
iii. If cardiac biomarkers are initially elevated above the local laboratory upper limit of normal, serial measurements must demonstrate that the biomarkers are falling.
d. Over 30 days prior to Baseline Procedure: PCI of non-target vessels performed greater than 30 days prior to baseline procedure whether or not successful and uncomplicated.
Patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule.
Angiographic inclusion criteria (visual estimate):
- Target lesion(s) must be located in a native coronary artery or bypass graft conduit with visually estimated diameter of ≥2.75 mm to ≤4.25 mm.
- Complex lesions are allowed including calcified lesions (lesion preparation with scoring/cutting and rotational atherectomy are allowed), presence of thrombus, CTO, bifurcation lesions, ostial RCA lesions, tortuous lesions, bare metal stent restenotic lesions, protected left main lesions, and saphenous vein graft lesions.
- Overlapping stents are allowed as long as the first stent implanted is the EluNIR 38 mm long stent
Exclusion Criteria:
General Exclusion Criteria:
- STEMI within 24 hours of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital or in whom enzyme levels (either CK-MB or Troponin) have not peaked.
- PCI within the 24 hours preceding the baseline procedure.
- Non-target lesion PCI in the target vessel within 12 months of the baseline procedure.
- History of stent thrombosis.
- Cardiogenic shock (defined as persistent hypotension (systolic blood pressure <90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including IABP.
- Subject is intubated.
- Known LVEF <30%.
- Relative or absolute contraindication to DAPT for 6 months in non-ACS patients and 12 months in ACS patients (including planned surgeries that cannot be delayed, or subject is indicated for chronic oral anticoagulant treatment).
- eGFR <30 mL/min
- Hemoglobin <10 g/dL.
- Platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
- White blood cell (WBC) count <3,000 cells/mm3.
- Clinically significant liver disease.
- Active peptic ulcer or active bleeding from any site.
- Bleeding from any site within the prior 8 weeks requiring active medical or surgical attention.
- If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath.
- History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Cerebrovascular accident or transient ischemic attack within the past 6 months, or any permanent neurologic defect attributed to CVA.
- Known allergy to the study stent components cobalt, nickel, chromium, molybdenum, Carbosil®, PBMA, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus, everolimus, or similar drugs or any other analogue or derivative or similar compounds).
- Known allergy to protocol-required concomitant medications such as aspirin, or DAPT (clopidogrel, prasugrel, ticagrelor), or heparin and bivalirudin, or iodinated contrast that cannot be adequately pre-medicated.
- Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduced life expectancy to <24 months (e.g. cancer, severe heart failure, severe lung disease).
- Patient is participating in or plans to participate in any other investigational drug or device clinical trial that has not reached its primary endpoint.
- Women who are pregnant or breastfeeding.
- Women who intend to become pregnant within 12 months after the baseline procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the baseline procedure).
- Patient has received an organ transplant or is on a waiting list for an organ transplant.
- Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the baseline procedure.
Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are allowed.
Angiographic Exclusion Criteria (visual estimate):
- Unprotected left main lesions ≥30%, or planned left main intervention.
- Bifurcation lesions with planned dual stent implantation.
- Stenting of lesions due to DES restenosis.
- Occlusive thrombus and/or a thrombus requiring thrombectomy in a target vessel
- Another lesion in a target or non-target vessel (including all side branches) is present that requires or has a high probability of requiring PCI within 12 months after the baseline procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: EluNIR 38mm
|
The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoint: Device Success
Time Frame: 30 day
|
Device success is defined as achievement of a final in-stent residual diameter stenosis of <50% (by QCA), using the assigned device only and without a device malfunction.
|
30 day
|
Primary Endpoint: No 30 Day MACE (Major Adverse Cardiac Events)
Time Frame: 30 Day
|
No 30 day MACE: MACE (Major Adverse Cardiac Events) is defined as the composite of cardiac death, any MI, or ischemia-driven TLR.
|
30 Day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EluNIR-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Stenosis
-
Biotronik (Beijing) Medical Device Ltd.Biotronik AGEnrolling by invitationNative Coronary Artery Stenosis | In-Stent Stenosis (Restenosis) of Coronary Artery StentChina
-
Axetis AGUnknownNative Coronary Artery StenosisNetherlands
-
Fundación Pública Andaluza Progreso y SaludUnknownUnprotected Left Main Coronary Artery StenosisSpain
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Institut Mutualiste MontsourisCompletedLeft Main Coronary Artery StenosisFrance
-
Tryton Medical, Inc.UnknownLeft Main Coronary Artery StenosisGermany
-
Columbia UniversityRecruitingLeft Anterior Descending Coronary Artery StenosisUnited States
-
Das Radiologische ZentrumHeidelberg UniversityRecruiting
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
-
Concept Medical Inc.Cardiovascular Research Foundation, New YorkNot yet recruitingCardiovascular Diseases | Coronary Artery Disease | Native Coronary Artery Stenosis
Clinical Trials on EluNIR Ridaforolimus Eluting Coronary Stent System
-
Medinol Ltd.CompletedMyocardial Ischemia | Cardiovascular Diseases | Coronary Disease | Coronary StenosisIsrael
-
Medinol Ltd.Completedde Novo or Restenosis LesionsJapan
-
Medinol Ltd.Not yet recruitingCoronary Artery Disease | Coronary Stenosis
-
Medinol Ltd.RecruitingIonMAN Trial- First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (IonMAN)Cardiovascular Diseases | Coronary Disease | Non-ST Elevated Myocardial Infarction | Coronary StenosisIsrael, Brazil
-
Shanghai Jiao Tong University School of MedicineCompletedCoronary Artery Disease | DiabetesChina
-
ReFlow Medical, Inc.Not yet recruiting
-
Atrium Medical CorporationTerminatedCoronary Artery DiseaseNew Zealand
-
Cook Group IncorporatedTerminatedCoronary Artery DiseaseGermany